Healio Rheumatology Current Issue
The following articles appeared in the print edition of Healio Rheumatology.
Table of Contents
- Elusive Target: A Rundown of the Drug Pipeline for Systemic Lupus Erythematosus
-
- 5 Important Items From the CCR Annual Meeting
- Glenohumeral Joint and Rheumatoid Arthritis T. Bradley Edwards, MD; Matthew D. Williams, MD
- FDA Accepts Biologics License Application for Review From Samsung Bioepis for Biosimilar to Infliximab
- Health Care Stakeholders Urge FDA to List Meaningful Suffixes for Biosimilars
- Neovacs Announces FDA Approval to Extend Phase 2b Clinical Lupus Trial to the United States
- Positive Results Announced in Phase 2 CLEAR Trial of CCX168 for ANCA-associated Vasculitis
- New Drug Development for SLE Offers Newfound Optimism and a Tinge of Caution Leonard H. Calabrese, DO
- The Patient With Gout
-
- Patients with Spondyloarthritis Experienced Limitations in Their Careers
- Study: New EULAR/ACR Classification Criteria Inadequate to Differentiate Polymyalgia Rheumatica From Mimicking Conditions
- Emerging Treatments Presented for Relapsing Vasculitis
- Highlights of HCV Research From Digestive Disease Week
- Congressional Subcommittee Debates Medicare Part B Demonstration Project
- White House Announces $121 Million Federal Investment in National Microbiome Initiative